Anergis Overview

  • Founded
  • 2001
Founded
  • Status
  • Private
  • Employees
  • 11
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $30.7M
Latest Deal Amount
  • Investors
  • 12

Anergis General Information

Description

Developer of disease-modifying allergy immunotherapy intended to improve the medical treatment of patients suffering from allergies. The company's immunotherapy is based on a proprietary allergy vaccines targeting commercially attractive indications, enabling patients to get a long-term cure for allergies and reduce the treatment time.

Contact Information

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • Biopôle Building SC-A
  • Route de la Corniche 4
  • 1066 Épalinges
  • Switzerland
+41 021 000 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Anergis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series B) 04-Apr-2016 $30.7M 000.00 000.00 Completed Generating Revenue
3. Grant 27-Sep-2013 000.00 000.00 Completed Generating Revenue
2. Later Stage VC (Series A) 28-Mar-2011 $19.6M $22.8M 000.00 Completed Generating Revenue
1. Seed Round $3.26M $3.26M Completed Startup
To view Anergis’s complete valuation and funding history, request access »

Anergis Executive Team (9)

Name Title Board Seat Contact Info
Gerard Farmer Ph.D Director, Regulatory Affairs
Vanya Beltrami Ph.D Vice President & Head, Manufacturing
Francois Spertini MD Founder, Chairman of Scientific Advisory Board & Vice Chairman of the Board of Directors
Vincent Charlon Ph.D Chief Executive Officer
You’re viewing 4 of 9 executive team members. Get the full list »

Anergis Board Members (9)

Name Representing Role Since
Francois Spertini MD Anergis Founder, Chairman of Scientific Advisory Board & Vice Chairman of the Board of Directors 000 0000
Klaus Schollmeier Ph.D Self Chairman 000 0000
Markus Hosang Ph.D BioMedPartners Board Member 000 0000
Sten Verland Ph.D Sunstone Life Science Ventures Board Member 000 0000
You’re viewing 4 of 9 board members. Get the full list »

Anergis Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Anergis Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BlueOcean Ventures Venture Capital Minority 000 0000 000000 0
Renaissance KMU Schweizerische Anlagestiftung PE/Buyout Minority 000 0000 000000 0
WJFS Family Office Minority 000 0000 000000 0
BB Biotech Ventures Venture Capital Minority 000 0000 000000 0
Novartis Venture Fund Corporate Venture Capital 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »